- Article
- Source: Campus Sanofi
- May 5, 2025
Severe Asthma Biomarker's
What is the clinical utility of monitoring changes in eosinophils, IgE, and fractional exhaled nitric oxide (FeNO) to assess the effectiveness of biologic treatments?
Eosinophils and FeNO - these clinical measurements can help us predict exacerbation risk and make wise decision on biological options.1 What is the clinical utility of monitoring changes in eosinophils, IgE, and fractional exhaled nitric oxide (FeNO) to assess the effectiveness of biologic treatments?
-
Tiotiu A. Biomarkers in asthma: state of the art. Asthma research and practice. 2018;4(1):10.
-
Wechsler ME, Klion AD, Paggiaro P, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(10):2695-709.
MAT-BH-2400426/V1/DEC 2024